Skip to Content

Institute of Biomedical Research Corp MRES

Morningstar Rating
$0.01 0.00 (3.90%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

MRES is trading at a 281% premium.
Price
$0.01
Fair Value
$3.42
Uncertainty
Extreme
1-Star Price
$8.59
5-Star Price
$6.57
Economic Moat
Tvlq
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MRES is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.01
Day Range
$0.010.01
52-Week Range
$0.000.03
Bid/Ask
$0.01 / $0.01
Market Cap
$490,477.55
Volume/Avg
95,817 / 680,034

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Institute of Biomedical Research Corp is a biomedical research and development company. The company is focused on alternative plant-based cannabinoids and mental health therapeutic research. The Institute has expanded its research to also include the augmentation of traditional medicine and the emerging science of medicinal mushrooms.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees

Valuation

Metric
MRES
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
MRES
Quick Ratio
Current Ratio
Interest Coverage
−520.29
Quick Ratio
No chart available

Profitability

Metric
MRES
Return on Assets (Normalized)
−12,186.34%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
−15,140.73%
Return on Assets
No chart available
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRFqrlwtpvqQppz$605.7 Bil
VRTX
Vertex Pharmaceuticals IncSbcwrftpKdslhh$116.3 Bil
REGN
Regeneron Pharmaceuticals IncCgzjvvdGtnczc$108.5 Bil
MRNA
Moderna IncSjgcgjjtlZjrb$62.9 Bil
BNTX
BioNTech SE ADRDgjyhskbJqjsn$23.9 Bil
ARGX
argenx SE ADRDpjwpphdMdww$21.6 Bil
ALNY
Alnylam Pharmaceuticals IncQbdcnbsrQfncfh$18.9 Bil
BMRN
Biomarin Pharmaceutical IncBxzzvtvLsbxyrd$14.3 Bil
INCY
Incyte CorpWfsbhgkrRmsvq$12.9 Bil
UTHR
United Therapeutics CorpYvtbwhdfKrtf$12.1 Bil

Sponsor Center